Hansoh Pharmaceutical (03692.HK) Announces Placement of 108 Million New Shares at HK$36.30, Raising Net Proceeds of Approximately HK$3.897 Billion

Hansoh Pharma (03692) announced that on August 20, 2025 (before trading hours), the company, the overall coordinators, and the placement agents entered into a placement agreement. Accordingly, the company agreed to appoint the placement agents, and the placement agents agreed to act as (individually and not jointly or jointly and severally) placement agents on behalf of the company, to procure subscribers or (if unable to procure subscription) subscribe themselves in accordance with and subject to the terms and conditions set out in the placement agreement at a placement price of HK$36.30 per placement share for 108 million placement shares.

The number of placement shares represents approximately 1.78% of the total enlarged issued share capital after the completion of the placement (assuming no changes to the total issued share capital from the date of this announcement until the completion date, except for the issuance of placement shares by the company). The placement price is HK$36.30 per placement share, representing a discount of approximately 6.49% compared to: (i) the closing price of HK$38.82 per share on the Stock Exchange on August 19, 2025 (being the last trading day immediately preceding the date of the placement agreement).

The net proceeds from the placing (after deducting placement commission, levies, and transaction fees) will amount to approximately HKD 3.897 billion. Based on this calculation, the net price per placed share will be approximately HKD 36.08. The company plans to allocate the net proceeds from the placing as follows: (i) approximately 65% will be used for (a) the research and development of new innovative drugs in therapeutic areas such as oncology, autoimmune diseases, central nervous system disorders, and metabolic diseases, and (b) licensing of innovative drugs and innovative technology platforms; (ii) approximately 25% will be used for (a) constructing new production facilities and R&D laboratories for innovative drugs, and (b) upgrading the group’s existing R&D laboratories and production facilities; and (iii) approximately 10% will be used for working capital and other general corporate purposes.